1 / 23

Asthma Management Considerations in Allergic Respiratory Disease Peter Socrates Creticos, M.D.

Asthma Management Considerations in Allergic Respiratory Disease Peter Socrates Creticos, M.D. World Allergy Congress - Cancun December 5, 2011. Dr. Creticos is engaged in current research with the following entities : - Greer Labs - Merck/Schering-Plough Corporation

rene
Download Presentation

Asthma Management Considerations in Allergic Respiratory Disease Peter Socrates Creticos, M.D.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Asthma Management Considerations in Allergic Respiratory Disease Peter Socrates Creticos, M.D. World Allergy Congress - Cancun December 5, 2011

  2. Dr. Creticos is engaged in current research with the following entities: - Greer Labs - Merck/Schering-Plough Corporation - Stallergenes - AHRQ Dr. Creticos has enduring consulting agreements with the following entities: - Merck Research - Sanofi-Aventis - Greer Labs Dr. Creticos has participated on ad-hoc SABs with the following entities: - Dynavax Technologies Inc. - Sanofi-Aventis - Genentech/Novartis - AstraZeneca - GlaxoSmithKline - Schering-Plough - Circassia - FDA - Stallergenes - Biomay

  3. Chief Complaint: • 20 year old female referred by primary physician • for evaluation and management of worsening • “hay fever” and seasonal asthma • History: • Perennial nasal congestion with distinct • seasonal exacerbations punctuated by • sneezing/itchy watery eyes/rhinorrhea/ • postnasal drip with cough • - describes moderate-severe symptomatology • in Spring-Summer (mid-April to late June) • and Fall (late August-October) • - Triggers: cut grass/ragweed/dust/cats/ • perfume/cigarette smoke

  4. History Continued: - Has tried various nasal steroids/antihistamine- decongestants/leukotriene antagonists with only partial relief - notes she does not “like to use” nasal steroids because they cause nasal bleeding - tried nasal antihistamine (azelastine) but could not tolerate taste - previously tried allergen immunotherapy in early teens but discontinued shots after six months due to repeated LLRs and one systemic reaction (hives and chest tightness occurring within 10 minutes of injection)

  5. History Continued: • By early teens, she began to appreciate EIA • with spring training and fall soccer season • - c/o mild/intermittent wheezing/chest • tightness/cough which respond to • albuterol prn (only required with exercise) • - no nocturnal asthma/no inhaled steroid • or oral steroid use/no ER visitation or • hospitalization for asthma • - since being placed on montelukast • (Singulair) + fexofenadine (Allegra) for • control of rhinitis, she feels that her • asthma has become less bothersome • - Triggers: pollen/exercise/viral infections/cats

  6. History Continued: • In college (Va) her episodes of asthma have • worsened and become more frequent, with • symptoms that correlate with peaks • of pollen seasons (May; late September) x • past 3 years + more persistent/prolonged • exacerbations with soccer • - she now finds herself using albuterol 4-5 • times during practice and frequently • throughout days when not playing soccer • - now notes nocturnal asthma occurring • 1-2x per week and she had an ER visit in • mid-September • - she has been referred for evaluation and • management considerations

  7. Allergy Profile: No known food/drug/bee sting sensitivity; eczema as toddler (worsened in early teens; now quiescent); tolerates NSAIDs Past History: Episodes of sinusitis occur ~ 1-2 x/year (Fall/early winter) - correlates with worsening rhinitis with yellow-greenish nasal discharge/facial discomfort/pain - usually requires one-two (7-10 days) courses of antibiotics to bring resolution

  8. Family History: Father & mother in good health (dad with asthma + hay fever); 12 yr old sister w/ allergic rhinitis Environmental History: Born in Maryland; resides 75-year old stone-timber home x 20 yrs; FHA/CAC/WWC/non-encased mattress/foam pillows; Pets: 1 cat (bedroom at home) At college, moved out of sorority house to 2-story apt w/ no air conditioning, old carpeting, and rabbit Work History/Social History: College junior; does not smoke or use alcohol/drugs; competitive soccer player

  9. Review of Systems: 14 systems queried: other positives include heartburn/menstrual cramps Physical: Well-developed white female; no acute distress; orientedx 3; BP: 118/68; pulse: 68; RR: 12; Hgt: 5 6”; Wt: 124; PEFR: 410/430 (445) HEENT:Conjuctiva clear; tympanic membranes intact;nares with mild edema (30%) of nostrils bilaterally with pale mucosa; no erosions/ ulcerations/polyps; oral mucosa unremarkable except for minimal drainage over the posterior pharynx; no adenopathy; Sinuses: non-tender;

  10. Physical Continued: Neck: supple withoutthyroid enlargement/no bruits; Chest: normal to percussion/ ausculation; no wheezing/rales/rhonchi; normal fremitus/egophony; CV: regular rate without murmur/gallop/click; Abdomen: soft/non-tender/ no palpable masses/no organomegaly; no bruits Extremities: no edema/normal pulses; Skin: no lesions; Musculoskeletal: intact; Neuro: intact. PFTs: FEV1: 79%; FVC: 91%; FEV1/FVC ratio: 87% [Interpretation: mild obstructive indices] PEFR (pre-exercise): 410/450 L/min (91%) PEFR (post-exercise): 320/450 L/min (71%) Response to bronchodilator: 28%

  11. Skin Test Evaluation: Primary (puncture) skin test reactivities: positive to trees (maple/oak/pecan); grasses (timothy/bermuda); weeds (ragweed); cat; dust mites Secondary (intradermal) skin test reactivities: positive toadditional trees (ash/poplar/elm); rabbit

  12. Assessment: 1) Seasonal allergic rhinitis/conjuctivitis a) trees/grass (spring); ragweed (fall) 2) Perennial allergic rhinitis a) dust mites/cat/rabbit 3) Persistent asthma a) allergic component b) exercise-induced component 4) Episodic sinusitis a) responds to antibiotics 5) Past history of eczema

  13. Plan/Treatment Strategies: Discuss environmental control and provide literature to patient Optimize rhinitis management plan: add nasal steroid to existing regimen [LTα (Singulair: 10 mg tab once daily) +/- fexofenadine (Allegra: 180 mg tab prn)] Optimize asthma management plan: a) initiate ICS + LABA/LAA combination agent; b) vs initiate ICS + maintain LTα; c) vs consider omalizumab (anti-IgE); d) re-attempt immunotherapy (?) 4) Develop EIA-management plan 5) Instruct & provide peak flow meter to patient

  14. Plan continued: 6) Rhinitis and Asthma Management plans reviewed and provided to the patient 7) Medication instructions reviewed/ samples provided/principal side effects of medicines discussed 8) Risks/benefits of immunotherapy reviewed with patient; treatment options outlined

  15. Clinical Consideration: Risks of Long-acting Beta-agonists in Asthma Therapy Citation: Age & Risks of FDA-approved Long-acting ß2-Adrenergic Receptor Agonists; AW McMahon, MS Levenson, BW McEvoy, et al. Pediatrics 128: 1147-54, 2011

  16. Findings: In a meta-analysis of 110 controlled clinical trials (61,000 subjects; age >4) a composite event incidence of 6.3 events per 1000 patient-years was observed [95%CI: 2.2-10.3] for using LABA vs not using LABA -- the incidence was observed to be age-dependent, with the largest difference in children [ages (4-11): 30.4 events per 1000 patient years (95%CI: 5.7- 55.1)] In the patient subgroup receiving concomitant ICS (n: 36,210) the risk declined [0.4 events per 1000 patient-years (95%CI: -3.8 – 4.6)] Conclusion: Serious asthma-related events associated with LABA use was observed to be greatest amongst children

  17. Clinical Consideration: Use of Leukotriene Antagonists as Controller Therapy in Asthma Management Citation: Leukotriene Antagonists as First-Line or Add-on Asthma Controller Therapy DP Price, SD Musgrave, L Shepstone, et al. N Engl J Med 364: 1695-1707, 2011

  18. Methods: Two “real world” multicenter clinical trials were conducted to evaluate the effectiveness of a LTRA as compared with either an ICS for 1st-line asthma-controller therapy or a LABA as add-on therapy in patients already receiving inhaled glucocorticoid therapy Patients (age: 12-80) with impaired asthma-related QOL(Mini AQLQ score < 6) or inadequate asthma control (ACQ score >1) were randomly assigned to 2-year open-label therapy

  19. Findings: Mean MiniAQLQ scores increased by 0.8-1.0 over the initial 2-year period of assessment in both clinical trials - equivalence in treatment effect, based on differences in MiniAQLQ scores between the two treatment groups, was met at 2 months [MiniAQLQ 95%CI: -0.3 – 0.3] - at 2 years, MiniAQLQ scores approached equivalence, with an adjusted mean difference between groups of -0.11 [95%CI: -0.35 – 0.13] in 1st-line controller therapy, and -0.11 [95%CI: -0.32 – 0.11] in the add-on therapy clinical trial Exacerbation rates and ACQ scores did not differ significantly between the two groups

  20. Conclusion: ■ Study results at 2 months suggest that LTRA therapy was equivalent to an inhaled corticosteroid as first-line controller therapy and to a LABA as add-on therapy in a diverse population of primary care asthma patients ▲ However, sustained equivalence was not observed at the 2-year endpoint of the clinical trials

  21. Clinical Consideration: Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma Citation: Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma SP Peters, SJ Kunselman, N Icitovic, et al. N Engl J Med 363: 1715-1726, 2010

  22. Methods: Three-way, double-blind, triple-dummy crossover trial involving 210 patients with asthma -- thestudy design evaluated the addition of tiotropium bromide to an inhaled glucocorticoid, as compared to doubling the dose of the inhaled corticosteroid, or simply adding a LABA to an inhaled corticosteroid * Tiotropium bromide is a long-acting anticholinergic agent approved in the U.S. for the treatment of chronic obstructive pulmonary disease but not asthma

  23. Findings: The use of tiotropium resulted in significant improvement in the primary outcome [PEF] as compared to doubling the dose of an inhaled glucocorticoid [mn diff: 25.8 L/min (p<0.001)] -- superiority was also shown for most secondary outcomes measured (DSS/ePEF/ACDs/ pre-BD FEV1) The addition of tiotropium was also non-inferior to the addition of salmeterol for all assessed outcomes and more effectively increased the pre-bronchodilator FEV1 [difference of 110 ml (p=0.003)] Conclusion: When added to an ICS, tiotropium improved symptoms and lung function in inadequately controlled asthmatics and its effects appeared to be comparable to that observed with the addition of a LABA

More Related